phenytoin has been researched along with Lymphoma in 57 studies
Lymphoma: A general term for various neoplastic diseases of the lymphoid tissue.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We report a patient with phenytoin-induced pseudolymphoma mimicking cutaneous T-cell lymphoma (CTCL)." | 8.78 | Phenytoin-induced pseudolymphoma. A report of a case and review of the literature. ( Buckley, C; Harris, DW; Ostlere, L; Rustin, MH; Sweny, P; Whittaker, S, 1992) |
| "Patients receiving phenytoin (PHT) may develop pseudolymphoma or, rare ly, malignant lymphoma." | 7.69 | Phenytoin-induced pseudolymphoma: reevaluation using modern molecular biology techniques. ( Jeng, YM; Su, IJ; Tien, HF, 1996) |
| "A pseudolymphomatous reaction involving subcutaneous tissue and underlying skeletal muscle is described in a woman who was receiving phenytoin sodium and phenobarbitone." | 7.66 | A pseudolymphomatous reaction in soft tissue associated with phenytoin sodium. ( Scott, CA; Wilden, JN, 1978) |
| "In vitro and in vivo immunologic studies were performed on a 28-year-old woman with phenytoin sodium-induced pseudolymphoma syndrome." | 7.65 | Phenytoin-induced pseudolymphoma syndrome: an immunologic study. ( Charlesworth, EN, 1977) |
| "We report a patient with phenytoin-induced pseudolymphoma mimicking cutaneous T-cell lymphoma (CTCL)." | 4.78 | Phenytoin-induced pseudolymphoma. A report of a case and review of the literature. ( Buckley, C; Harris, DW; Ostlere, L; Rustin, MH; Sweny, P; Whittaker, S, 1992) |
| " Using a PEG 3350 screen combined with detergents, and developed from our experiments with an IgG2a kappa antibody specific for canine lymphoma cells, crystals have now been obtained of two of these four immunoglobulins, an antiphenytoin and an antiphenobarbital antibody." | 3.69 | Crystallization of intact monoclonal antibodies. ( Harris, LJ; McPherson, A; Skaletsky, E, 1995) |
| "Patients receiving phenytoin (PHT) may develop pseudolymphoma or, rare ly, malignant lymphoma." | 3.69 | Phenytoin-induced pseudolymphoma: reevaluation using modern molecular biology techniques. ( Jeng, YM; Su, IJ; Tien, HF, 1996) |
| "A pseudolymphomatous reaction involving subcutaneous tissue and underlying skeletal muscle is described in a woman who was receiving phenytoin sodium and phenobarbitone." | 3.66 | A pseudolymphomatous reaction in soft tissue associated with phenytoin sodium. ( Scott, CA; Wilden, JN, 1978) |
| "In vitro and in vivo immunologic studies were performed on a 28-year-old woman with phenytoin sodium-induced pseudolymphoma syndrome." | 3.65 | Phenytoin-induced pseudolymphoma syndrome: an immunologic study. ( Charlesworth, EN, 1977) |
| "Decreased libido and impotence were more common in patients given primidone." | 2.66 | Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. ( Browne, TR; Collins, JF; Cramer, JA; Delgado-Escueta, AV; Mattson, RH; McCutchen, CB; McNamara, JO; Smith, DB; Treiman, DM; Williamson, PD, 1985) |
| "Carbamazepine was given to 15 patients, phenytoin to 12, and barbiturate to 7, respectively; 42 patients also received corticosteroids." | 1.30 | Late radiation toxicity after whole brain radiotherapy: the influence of antiepileptic drugs. ( Leicht, A; Motaref, B; Nestle, U; Nieder, C; Niewald, M; Schnabel, K, 1999) |
| "Phenytoin is a hydantoin-type anticonvulsive agent used extensively for nearly sixty years in the prophylactic treatment of grand mal and psychomotor seizures." | 1.29 | Perspective on the carcinogenic potential of phenytoin based on rodent tumor bioassays and human epidemiological data. ( de la Iglesia, FA; Dethloff, LA; Goldenthal, E; Gough, A; Graziano, MJ, 1996) |
| "An initial diagnosis of malignant lymphoma was made, and recurrent hospitalizations and treatment with cytotoxic drugs ensued." | 1.27 | Phenytoin-induced lymphadenopathy. ( Howrie, DL; Schwinghammer, TL, 1983) |
| "Phenytoin therapy was associated with low immunoglobulin A (21%), failure of antibody response to Salmonella typhi antigen (9%), absence of delayed hypersensitivity (D." | 1.25 | Depression of immunological function in patients treated with phenytoin sodium (sodium diphenylhydantoin). ( Burness, FR; Forbes, IJ; Rischbieth, RH; Sorrell, TC, 1971) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 44 (77.19) | 18.7374 |
| 1990's | 10 (17.54) | 18.2507 |
| 2000's | 2 (3.51) | 29.6817 |
| 2010's | 1 (1.75) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| ROSENFELD, S | 1 |
| SWILLER, AI | 1 |
| SHENOY, YM | 1 |
| MORRISON, AN | 1 |
| Scheinfeld, N | 1 |
| Lee, KC | 1 |
| Garcia, PA | 1 |
| Alldredge, BK | 1 |
| Duggan, MA | 1 |
| Court, JB | 1 |
| Amadori, G | 1 |
| Fiore, D | 1 |
| Gabryś, K | 1 |
| Medraś, E | 1 |
| Kowalski, P | 1 |
| Gola, A | 1 |
| Isobe, T | 1 |
| Tomita, M | 1 |
| Matsumoto, J | 1 |
| Itoh, T | 1 |
| Fujita, T | 1 |
| Schwinghammer, TL | 1 |
| Howrie, DL | 1 |
| Matoba, K | 1 |
| Katsumata, T | 1 |
| Kakei, M | 1 |
| Kuwata, H | 1 |
| Nakazawa, H | 1 |
| Saigeni, K | 1 |
| Okabe, H | 1 |
| Chin, S | 1 |
| Maekawa, K | 1 |
| Katsuoka, K | 1 |
| Oh-Ida, M | 1 |
| Atari, H | 1 |
| Rosenthal, CJ | 1 |
| Noguera, CA | 1 |
| Coppola, A | 1 |
| Kapelner, SN | 1 |
| Bedros, AA | 1 |
| Mann, JP | 1 |
| Adams, JD | 1 |
| Vellucci, A | 1 |
| Galanti, G | 1 |
| Pezzella, B | 1 |
| De Longis, P | 1 |
| Colacecchi, C | 1 |
| Abbondazo, SL | 1 |
| Irey, NS | 1 |
| Frizzera, G | 1 |
| Sigal, M | 1 |
| Pulik, M | 1 |
| Harris, LJ | 1 |
| Skaletsky, E | 1 |
| McPherson, A | 1 |
| Jeng, YM | 1 |
| Tien, HF | 1 |
| Su, IJ | 1 |
| Dethloff, LA | 1 |
| Graziano, MJ | 1 |
| Goldenthal, E | 1 |
| Gough, A | 1 |
| de la Iglesia, FA | 1 |
| Nieder, C | 1 |
| Leicht, A | 1 |
| Motaref, B | 1 |
| Nestle, U | 1 |
| Niewald, M | 1 |
| Schnabel, K | 1 |
| Gleichmann, E | 1 |
| van Elven, F | 1 |
| Gleichmann, H | 1 |
| Lapes, MJ | 1 |
| Vivacqua, RJ | 1 |
| Antoniades, K | 1 |
| Halevy, S | 1 |
| Feuerman, EJ | 1 |
| Bedoya, V | 1 |
| Krueger, GR | 2 |
| Bedoya, VA | 1 |
| Matsuo, T | 1 |
| Matsumoto, A | 1 |
| Miyasaki, K | 1 |
| Wilden, JN | 1 |
| Scott, CA | 1 |
| Lorand, IG | 1 |
| Hadler, WA | 1 |
| Prigenzi, LS | 1 |
| Charlesworth, EN | 1 |
| Bluming, AZ | 1 |
| Li, FP | 1 |
| Willard, DR | 1 |
| Goodman, R | 1 |
| Vawter, G | 1 |
| Fried, MP | 1 |
| Sunwoo, Y | 1 |
| Ghosh, C | 1 |
| Lazarus, HM | 1 |
| Hewlett, JS | 1 |
| Creger, RJ | 1 |
| Harris, DW | 1 |
| Ostlere, L | 1 |
| Buckley, C | 1 |
| Whittaker, S | 1 |
| Sweny, P | 1 |
| Rustin, MH | 1 |
| Tittle, TV | 1 |
| Schaumann, BA | 1 |
| Rainey, JE | 1 |
| Taylor, K | 1 |
| Rodríguez-García, JL | 1 |
| Sánchez-Corral, J | 1 |
| Martínez, J | 1 |
| Bellas, C | 1 |
| Aguado, M | 1 |
| Serrano, M | 1 |
| Cooke, LE | 1 |
| Hardin, TC | 1 |
| Hendrickson, DJ | 1 |
| DeSwarte, RD | 1 |
| Brodell, RT | 1 |
| Santa Cruz, DJ | 1 |
| Mattson, RH | 1 |
| Cramer, JA | 1 |
| Collins, JF | 1 |
| Smith, DB | 1 |
| Delgado-Escueta, AV | 1 |
| Browne, TR | 1 |
| Williamson, PD | 1 |
| Treiman, DM | 1 |
| McNamara, JO | 1 |
| McCutchen, CB | 1 |
| Pereira, A | 1 |
| Cervantes, F | 1 |
| Rozman, C | 1 |
| Krüger, G | 1 |
| Kruger, GR | 1 |
| Harris, D | 1 |
| Dorfman, RF | 1 |
| Warnke, R | 1 |
| Sorrell, TC | 1 |
| Forbes, IJ | 1 |
| Burness, FR | 1 |
| Rischbieth, RH | 1 |
| Sisca, TS | 1 |
| Fraumeni, JF | 1 |
| Miller, RW | 1 |
| Kopec, M | 1 |
| Krasznai, G | 1 |
| Szegedi, G | 1 |
| Hyman, GA | 1 |
| Sommers, SC | 1 |
| Oates, RK | 1 |
| Tonge, RE | 1 |
| Alberto, P | 1 |
| Cougn, R | 1 |
| Maurice, P | 1 |
| Weber, J | 1 |
| Bercel, NA | 1 |
| Henstell, HH | 1 |
| Choovivathanavanich, P | 1 |
| Wallace, EM | 1 |
| Scaglione, PR | 1 |
| Gams, RA | 1 |
| Schreiber, MM | 1 |
| McGregor, JG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open Prospective Randomised Long-Term Effectiveness Study, Comparing Best Medical Practice With or Without Adjunctive VNS Therapy in Patients 16 Years and Older With Pharmaco-resistant Partial Epilepsy[NCT00522418] | Phase 4 | 122 participants (Actual) | Interventional | 2006-02-28 | Terminated (stopped due to Insufficient enrollment) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Adverse Events Profile (AEP) is a 19-item scale used as a systematic measure of adverse effects from antiepileptic drugs (AEDs). Scores range from 19-76; higher scores indicate high prevelance and severity of adverse events. (NCT00522418)
Timeframe: Mean change from baseline AEP Score at 12 months
| Intervention | Units on a scale (Mean) |
|---|---|
| VNS Therapy | -6.0 |
| Best Medical Practice | -3.2 |
The Center for Epidemiologic Studies Depression Scale (CES-D) includes 20 items comprising six scales reflecting major dimensions of depression: depressed mood, feelings of guilt and worthlessness, feelings of helplessness and hopelessness, psychomotor retardation, loss of appetite, and sleep disturbance. Possible range of scores is 0 to 60, higher scores indicate more depressive symptoms. (NCT00522418)
Timeframe: Mean change from baseline CES-D Score at 12 months
| Intervention | Units on a Scale (Mean) |
|---|---|
| VNS Therapy | -2.2 |
| Best Medical Practice | 0.5 |
The Neurological Disorders Depression Inventory for Epilepsy (NDDI-E) is a 6-item questionnaire validated to screen for depression in people with epilepsy. Scores range from 6 to 24, with higher scores indicating more depressive symptoms. (NCT00522418)
Timeframe: Mean change from baseline NDDI-E Score at 12 months
| Intervention | Units on a Scale (Mean) |
|---|---|
| VNS Therapy | -1.0 |
| Best Medical Practice | -0.2 |
Change from baseline in number of AED medications by visit (NCT00522418)
Timeframe: Change from baseline in number of AEDs at 12 months
| Intervention | Number of AEDs Taken (Median) |
|---|---|
| VNS Therapy | 0 |
| Best Medical Practice | 0 |
The Clinical Global Impression scale (CGI-I) is a 7 point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention Scores range from 1-7: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. (NCT00522418)
Timeframe: Mean change from baseline CGI-I Score at 12 months
| Intervention | Units on a Scale (Mean) |
|---|---|
| VNS Therapy | -0.8 |
| Best Medical Practice | -0.3 |
Percent change in total seizuires per week from baseline at 12 months (NCT00522418)
Timeframe: Mean percent change from baseline in seizure frequency at 12 months
| Intervention | Percent Change (Mean) |
|---|---|
| VNS Therapy | -19.1 |
| Best Medical Practice | -1.0 |
QOLIE-89 contains 17 multi-item measures of overall quality of life, emotional well-being, role limitations due to emotional problems, social support, social isolation, energy/fatigue, worry about seizure, medication effects, health discouragement, work/driving/social function, attention/concentration, language, memory, physical function, pain, role limitations due to physical problems, and health perceptions. Range of values 0-100. Higher scores reflect better quality of life; lower ones, worse quality of life. (NCT00522418)
Timeframe: Mean change from baseline QOLIE-89 Overall Score at 12 months
| Intervention | units on a scale (Mean) |
|---|---|
| VNS Therapy | 5.5 |
| Best Medical Practice | 1.2 |
Response Rate is defined as the percent of participants who are responders. A Responder is defined as participants with a reduction of at least 50% or 75% in seizure frequency from baseline to the seizure count evaluation period. (NCT00522418)
Timeframe: Number of Responders at 12 Months
| Intervention | participants (Number) |
|---|---|
| VNS Therapy | 10 |
| Best Medical Practice | 7 |
QOLIE-89 contains 17 multi-item measures of overall quality of life. Range of values 0-100. Higher scores reflect better quality of life; lower ones, worse quality of life. Adverse Events Profile (AEP) is a 19-item scale used as a systematic measure of adverse effects from antiepileptic drugs (AEDs). Scores range from 19-76; higher scores indicate high prevelance and severity of adverse events. (NCT00522418)
Timeframe: Change from baseline up to 12 months
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| VNS Therapy | Best Medical Practice | |
| Baseline Adverse Event Profile Score < 40 | 3.3 | 0.5 |
QOLIE-89 contains 17 multi-item measures of overall quality of life. Range of values 0-100. Higher scores reflect better quality of life; lower ones, worse quality of life. Adverse Events Profile (AEP) is a 19-item scale used as a systematic measure of adverse effects from antiepileptic drugs (AEDs). Scores range from 19-76; higher scores indicate high prevelance and severity of adverse events. (NCT00522418)
Timeframe: Change from baseline up to 12 months
| Intervention | Units on a Scale (Least Squares Mean) | |
|---|---|---|
| VNS Therapy | Best Medical Practice | |
| Baseline Adverse Event Profile Score >= 40 | 3.3 | 0.7 |
10 reviews available for phenytoin and Lymphoma
| Article | Year |
|---|---|
Impact of phenytoin therapy on the skin and skin disease.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Child; Connective Tissue Diseases; Drug Eruptio | 2004 |
Lymphadenopathy in children.
Topics: Adolescent; Autoimmune Diseases; Biopsy; Child; Child, Preschool; Head; Hodgkin Disease; Humans; Hyp | 1981 |
[Drug-induced pseudolymphoma with predominantly cutaneous manifestation].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Carbamazepine; Female; France; Humans; | 1993 |
Phenytoin-induced pseudolymphoma. A report of a case and review of the literature.
Topics: Adult; Diagnosis, Differential; Humans; Lymphoma; Lymphoma, T-Cell, Cutaneous; Male; Phenytoin | 1992 |
Drug allergy: an overview.
Topics: Anaphylaxis; Anemia; Boston; Desensitization, Immunologic; Drug Hypersensitivity; Fever; Humans; Liv | 1986 |
Cutaneous pseudolymphomas.
Topics: Diagnosis, Differential; Humans; Hyperplasia; Immunoblastic Lymphadenopathy; Lymphocytes; Lymphoma; | 1985 |
Lymphadenopathy simulating the malignant lymphomas.
Topics: Animals; Biopsy; Dermatitis; Drug Hypersensitivity; Herpes Zoster; Humans; Hyalin; Hyperplasia; Infe | 1974 |
Drug-induced cancer.
Topics: Alkylating Agents; Animals; Carcinogens; Diethylstilbestrol; Drug-Related Side Effects and Adverse R | 1972 |
[New data evidencing the role of antigenic stimulation in the pathogenesis of neoplasms of the lymphatic and plasmocytic systems. I. Can drug-induced hypersensitivity reactions lead to neoplastic proliferation in the lymphatic system?].
Topics: Adjuvants, Immunologic; Antigens, Neoplasm; Antistreptolysin; Diagnosis, Differential; Drug Hypersen | 1972 |
[Lymphadenopathies caused by drugs].
Topics: Adolescent; Adult; Animals; Carcinogens; Female; Humans; Lymph Nodes; Lymphatic Diseases; Lymphoma; | 1969 |
2 trials available for phenytoin and Lymphoma
| Article | Year |
|---|---|
Fluctuation of serum phenytoin concentrations during autologous bone marrow transplant for primary central nervous system tumors.
Topics: Adult; Anticonvulsants; Astrocytoma; Bone Marrow Transplantation; Brain Neoplasms; Carbamazepine; Fe | 1992 |
Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures.
Topics: Adolescent; Adult; Aged; Carbamazepine; Clinical Trials as Topic; Double-Blind Method; Epilepsies, P | 1985 |
45 other studies available for phenytoin and Lymphoma
| Article | Year |
|---|---|
Phenytoin and phenytoin sodium.
Topics: Animals; Anticonvulsants; Carcinogens; Humans; Leukemia; Lymphoma; Phenytoin; Sodium | 2011 |
Syndrome simulatingqymphosarcoma induced by diphenylhydantoin sodium.
Topics: Disease; Humans; Hydantoins; Lymph Nodes; Lymphatic Diseases; Lymphoma; Lymphoma, Non-Hodgkin; Pheny | 1961 |
Clinical features of status epilepticus in patients with HIV infection.
Topics: Adult; Anti-Retroviral Agents; Anticonvulsants; Benzodiazepines; Brain Neoplasms; Central Nervous Sy | 2005 |
A proposed mechanism of production of the autoimmune and lymphoproliferative side-effects of beta-adrenergic-site-blocking drugs and hydantoin anticonvulsants.
Topics: Adrenergic beta-Antagonists; Animals; Autoimmune Diseases; Carcinogens; Cyclic AMP; Ethanolamines; F | 1981 |
[Diagnostic problems in hydantoin immunopathy. Review of the literature and description of 3 cases].
Topics: Adolescent; Adult; Female; Fluorescent Antibody Technique; Humans; Immunoblastic Lymphadenopathy; Ki | 1984 |
[Development of malignant lymphoma during anticonvulsant therapy].
Topics: Epilepsy; Gastrointestinal Neoplasms; Humans; Lung Neoplasms; Lymphoma; Male; Middle Aged; Phenytoin | 1983 |
Hematologic and immunologic aberrations in patients under diphenylhydantoin administration.
Topics: Adolescent; Aged; Anticonvulsants; Arthritis, Rheumatoid; Female; Humans; Infectious Mononucleosis; | 1983 |
Phenytoin-induced lymphadenopathy.
Topics: Humans; Lymph Nodes; Lymphatic Diseases; Lymphoma; Male; Middle Aged; Phenytoin | 1983 |
[A case of primary B-cell origin lymphoma of the stomach seen during diphenylhydantoin therapy (author's transl)].
Topics: Adult; B-Lymphocytes; Female; Humans; Lymphoma; Phenytoin; Stomach Neoplasms | 1981 |
Pseudolymphoma with mycosis fungoides manifestations, hyperresponsiveness to diphenylhydantoin, and lymphocyte disregulation.
Topics: Adolescent; Adult; B-Lymphocytes; Female; Humans; Lymphoma; Male; Microscopy, Electron; Middle Aged; | 1982 |
Localized cutaneous pseudolymphoma associated with phenytoin therapy: a case report.
Topics: Child; Female; Humans; Lymphoma; Phenytoin; Skin Neoplasms | 1981 |
[Case of "exanthematous pseudolymphoma" due to diphenylhydantoin hypersensitivity with a transitory immunologic deficit].
Topics: Adolescent; Drug Hypersensitivity; Exanthema; Humans; Immunologic Deficiency Syndromes; Lymphoma; Ma | 1980 |
Dilantin-associated lymphadenopathy. Spectrum of histopathologic patterns.
Topics: Adult; Aged; Female; Humans; Hyperplasia; Immunophenotyping; Lymphatic Diseases; Lymphoma; Male; Mid | 1995 |
Crystallization of intact monoclonal antibodies.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Neoplasm; Antibody Specificity; Crystallization; Crysta | 1995 |
Phenytoin-induced pseudolymphoma: reevaluation using modern molecular biology techniques.
Topics: Adolescent; Biopsy; Blotting, Southern; Chromosome Aberrations; Diagnosis, Differential; Epilepsy, T | 1996 |
Perspective on the carcinogenic potential of phenytoin based on rodent tumor bioassays and human epidemiological data.
Topics: Animals; Anticonvulsants; Carcinogenicity Tests; Dose-Response Relationship, Drug; Female; Humans; L | 1996 |
Late radiation toxicity after whole brain radiotherapy: the influence of antiepileptic drugs.
Topics: Actuarial Analysis; Adult; Aged; Aged, 80 and over; Analysis of Variance; Anticonvulsants; Atrophy; | 1999 |
Immunoblastic lymphadenopathy, systemic lupus erythematosus, and related disorders. Possible pathogenetic pathways.
Topics: Animals; Autoantibodies; B-Lymphocytes; Drug Hypersensitivity; Graft vs Host Reaction; Humans; Immun | 1979 |
Letter: Immunoblactic lymphadenopathy associated with phenytoin (diphenylhydantoin).
Topics: Aged; Antibody-Producing Cells; Female; Humans; Lymphocytes; Lymphoma; Phenytoin | 1976 |
Psuedolymphoma syndrome.
Topics: Diagnosis, Differential; Drug Eruptions; Humans; Lymphoma; Male; Middle Aged; Phenytoin; Skin; Skin | 1977 |
Ultrastructural studies on hydantoin induced lymphomas in mice.
Topics: Animals; Female; Hydantoins; Lymphoma; Mice; Phenytoin | 1978 |
Hydantoin-induced lymphadenopathies and lymphomas: experimental studies in mice.
Topics: Animals; Female; Immunoblastic Lymphadenopathy; Lymphoma; Lymphoma, Non-Hodgkin; Mice; Mice, Inbred | 1978 |
[A case of diphenylhydantoin-induced pseudo-pseudolymphoma (author's transl)].
Topics: Diagnosis, Differential; Female; Humans; Lymphoma; Middle Aged; Phenytoin | 1977 |
A pseudolymphomatous reaction in soft tissue associated with phenytoin sodium.
Topics: Adult; Female; Humans; Lymphoma; Muscles; Phenytoin; Soft Tissue Neoplasms | 1978 |
Morphological changes in the lymphoid organs induced by diphenylhydantoin sodium (DPH).
Topics: Animals; Female; Lymph Nodes; Lymphoid Tissue; Lymphoma; Organ Size; Phenytoin; Plasma Cells; Rats; | 1976 |
Phenytoin-induced pseudolymphoma syndrome: an immunologic study.
Topics: Adult; Antibody Formation; Drug Hypersensitivity; Epilepsy; Female; Humans; Hypersensitivity, Delaye | 1977 |
Spontaneous regression of sarcoma.
Topics: B-Lymphocytes; Diagnosis, Differential; Humans; Hyperthyroidism; Immunosuppression Therapy; Infectio | 1976 |
Malignant lymphoma after diphenylhydantoin (dilantin) therapy.
Topics: Adult; Female; Hodgkin Disease; Humans; Lymphoma; Male; Middle Aged; Phenytoin | 1975 |
Anticonvulsant-induced lymphoma.
Topics: Adult; Head and Neck Neoplasms; Humans; Lymphoma; Phenytoin; Vocal Cord Paralysis | 1975 |
Segregation of the growth slowing effects of valproic acid from phenytoin and carbamazepine on lymphoid tumor cells.
Topics: Carbamazepine; Cell Division; Culture Techniques; Humans; Kinetics; Leukemia; Lymphoma; Phenytoin; R | 1992 |
Phenytoin-induced benign lymphadenopathy with solid spleen lesions mimicking a malignant lymphoma.
Topics: Aged; Aged, 80 and over; Diagnosis, Differential; Female; Humans; Lymphatic Diseases; Lymphoma; Phen | 1991 |
Phenytoin-induced pseudolymphoma with mycosis fungoides manifestations.
Topics: Adult; Humans; Lymphoma; Male; Mycosis Fungoides; Phenytoin; Skin Neoplasms | 1988 |
[Macrocytic anemia due to folic acid deficiency and non-Hodgkin's lymphoma associated with prolonged diphenylhydantoin ingestion].
Topics: Aged; Anemia, Macrocytic; Epilepsy; Female; Folic Acid Deficiency; Humans; Lymphoma; Phenytoin; Time | 1985 |
[Pathogenesis of lymphoreticular neoplasms in transplant recipients].
Topics: Animals; Antilymphocyte Serum; Cell Transformation, Neoplastic; Histocompatibility; Humans; Immunosu | 1970 |
Is phenytoin carcinogenic?
Topics: Carcinogens; Cell Transformation, Neoplastic; Epilepsy; Humans; Lymphatic Diseases; Lymphoma; Phenyt | 1971 |
Is phenytoin carcinogenic?
Topics: Animals; Female; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Mice; Mice, Inbre | 1972 |
Depression of immunological function in patients treated with phenytoin sodium (sodium diphenylhydantoin).
Topics: Adolescent; Adult; Aged; Antibody Formation; Antigens, Bacterial; Child; Epilepsy; Hodgkin Disease; | 1971 |
An unusual dual hypersensitivity reaction induced by diphenylhydantoin.
Topics: Dermatitis, Exfoliative; Drug Hypersensitivity; Female; Humans; Leukocyte Count; Lymphoma; Middle Ag | 1973 |
The development of Hodgkin's disease and lymphoma during anticonvulsant therapy.
Topics: Adult; Aged; Anticonvulsants; Child; Epilepsy; Epilepsy, Absence; Epilepsy, Post-Traumatic; Epilepsy | 1966 |
Phenytoin and the pseudolymphoma syndrome.
Topics: Child, Preschool; Diagnosis, Differential; Humans; Lymphatic Diseases; Lymphoma; Male; Phenytoin; Sk | 1971 |
[3 cases of malignant lymphoma or pseudolymphoma in epileptics treated with diphenylhydantoin].
Topics: Adult; Epilepsy; Female; Hodgkin Disease; Humans; Lymphoma; Male; Phenytoin | 1971 |
The relationship between some anticonvulsants and tumors of the blood forming organs.
Topics: Adult; Agranulocytosis; Anticonvulsants; Female; Genetics, Medical; Humans; Hydantoins; Leukocytes; | 1970 |
Pseudolymphoma induced by diphenylhydantoin.
Topics: Child; Epilepsy; Humans; Lymphoma; Male; Phenytoin; Skull Fractures | 1970 |
Pseudolymphoma induced by diphenylhydantoin.
Topics: Epilepsy; Humans; Lymphoma; Phenytoin | 1970 |
Pseudolymphoma syndrome. A sensitivity to anticonvulsant drugs.
Topics: Biopsy; Blood Cell Count; Blood Chemical Analysis; Chlordiazepoxide; Drug Hypersensitivity; Female; | 1968 |